Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Merck's Breakthrough Therapy Designation, Sonoma Surges On Sanitizer News, Sanofi-Glaxo And More
12:00am, Wednesday, 29'th Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 28)
Axonics Modulation Technologies Inc (NASDAQ: AXNX)
Capricor Therapeutics Inc (NASDAQ: CAPR)
Fulgent Genetics Inc...
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT)
Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...
Nkarta raises nearly $290 million in IPO
08:39pm, Tuesday, 14'th Jul 2020
Nkarta Inc. said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments. On Friday, the biotech company
SOUTH SAN FRANCISCO, Calif., July 14, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies.
U.S. IPO Weekly Recap: Preclinical Biotech Nkarta Pops 166% In A 5 IPO Week
08:22am, Sunday, 12'th Jul 2020
Three biotechs, two Chinese issuers, and one SPAC went public this past week. Preclinical oncology biotech Nkarta popped 166% in the best first-day return for a $10+ million IPO since 2015.
Nkarta's stock triples out of the gate, then pulls back
03:30pm, Friday, 10'th Jul 2020
Shares of Nkarta Inc. tripled out of the gate Friday, after the biotechnology company's initial public offering priced above its expected range. The first trade of the stock was at $54.75, or 204.2%
Biotech Nkarta prices IPO at $18 a share, above its price range
12:09pm, Friday, 10'th Jul 2020
Nkarta Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million. The company upsized the deal on Thurs
Nkarta Announces Pricing of Initial Public Offering
04:44am, Friday, 10'th Jul 2020
SOUTH SAN FRANCISCO, July 10, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat.
U.S. IPO Week Ahead: Third Quarter Kicks Off With China's Largest Gay Dating App
02:05pm, Friday, 03'rd Jul 2020
BlueCity Holdings plans to raise $85 million at a $614 million market cap. Quhuo plans to raise $27 million at a $450 million market cap. Nkarta plans to raise
Nkarta Begins U.S. IPO Rollout
06:06pm, Monday, 22'nd Jun 2020
Nkarta has filed to raise $100 million in a U.S. IPO, although the final figure may differ. The firm is developing cell therapies for blood and other cancers. N
U.S. IPO Weekly Recap: Royalty Pharma Takes The Crown In 5 IPO Week
11:05am, Saturday, 20'th Jun 2020
Five IPOs and one SPAC went public this past week led by Royalty Pharma. Healthcare continued to dominate, with all five IPOs coming from the sector. Seven IPOs
